CAC40 Drops Below 7,400 Points: Analyzing the Decline

The Paris Stock Exchange has dipped nearly 0.7%, influenced by declines in STMicro and URW. Meanwhile, the U.S. is bracing for a crucial earnings season, particularly from major banks, which could shape market sentiment. While S&P 500 earnings are projected to rise, uncertainties remain regarding inflation, interest rates, and potential tariffs under Donald Trump’s administration. Additionally, bioMérieux plans to acquire SpinChip Diagnostics, and Sanofi has received approval for its multiple myeloma treatment in China.

Paris Stock Exchange Takes a Dip

This morning, the Paris Stock Exchange is experiencing a decline of nearly 0.7%, hovering around 7380 points. This downturn is primarily attributed to STMicro, which has seen a drop of 3.6%, and URW, which is down by 2.5%.

U.S. Earnings Season on the Horizon

Meanwhile, across the Atlantic, Wall Street is gearing up for a pivotal week filled with significant quarterly earnings reports from major American corporations. These results are crucial as they will set the market’s tone for the forthcoming sessions.

The spotlight will shine on major American banks during this first week of earnings season, with reports from Citi, Goldman Sachs, JPMorgan, and Wells Fargo expected on Wednesday. The following day will feature earnings from Bank of America and Morgan Stanley.

Insights from these financial giants will provide investors with valuable perspectives on the current economic landscape, consumer behavior, and the overall economic outlook in the United States.

FactSet reports that the earnings of companies within the S&P 500 index are projected to rise by an average of 11.7% year-on-year for the fourth quarter, marking the most robust increase since the end of 2021.

As evidenced by last Friday’s strong U.S. employment data, positive statistics are no longer sufficient to drive market gains, as they indicate a reduction in monetary easing.

This earnings season will reveal if the New York Stock Exchange can regain its upward trajectory, particularly since the S&P 500 is currently trading at 21.5 times its earnings—significantly above its ten-year historical average of 18.2.

However, the commencement of earnings season does not overshadow ongoing developments across the Atlantic, including uncertainties surrounding Donald Trump’s policy direction, rising inflation, and heightened tensions regarding bond yields.

Long-term U.S. interest rates reached new highs last Friday, following a surprisingly strong employment report.

Furthermore, the earnings season kicks off amidst escalating trade uncertainties just a week before Donald Trump’s inauguration as the 47th president of the United States next Monday. During his campaign, he indicated plans to impose tariffs on Chinese imports of up to 60% and implement taxes on goods from other nations ranging from 10% to 20%.

The potential introduction of ‘universal’ sustainable tariffs could negatively impact stocks, particularly within the retail, automotive, technology, semiconductor, and certain industrial sectors.

Given these uncertainties and the less appealing valuations, investors are contemplating whether it is time to secure profits from American stocks, as concerns about a significant market correction loom over the coming months.

In a recent note, Goldman Sachs strategists assessed a 30% probability of a global stock market decline of at least 10% within the next three months, and over 20% within the next year.

Against this backdrop, gold is regaining attraction among investors, nearing its historical highs reached over two months ago.

Additionally, oil prices are on the rise, following the Biden administration’s decision to implement new sanctions targeting the Russian energy sector. This morning, Brent crude is up nearly 1.5%, trading at around $81.1 per barrel.

In corporate news from France, bioMérieux has announced an agreement to acquire SpinChip Diagnostics, a Norwegian firm in which it has held a 20% minority stake since March 2024.

Additionally, Sanofi has reported that the Chinese NMPA has approved its Sarclisa treatment in combination with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma who have undergone at least one prior treatment.

Related Articles